This report outlines the process of monoclonal antibody drug patent research with the investigation of BeiGene patent portfolio related to its tislelizumab monoclonal antibody.

Tislelizumab, referred to as bazeleus, represents a humanized IgG4 monoclonal antibody targeting PD-1.

Keytruda has rapidly ascended to become the top-selling drug in the market, underscoring the significance of monoclonal antibodies in modern medicine.

Based on the characteristics of ADC drugs, we have summarized the process for conducting patent research on ADC drugs.

Based on the characteristics of ADC drugs, we have summarized the process for conducting patent research on ADC drugs.

Currently, 272 ADC drugs have been initiated for clinical trials globally. Excluding the market withdrawal of Belantamab mafodotin (Blenrep®), 14 approved ADC products remain available.

Based on the characteristics of siRNA drugs, we have summarized the process for conducting patent research on siRNA drugs.

Based on the characteristics of siRNA drugs, we have summarized the process for conducting patent research on siRNA drugs.

Alnylam announced on June 14, 2022, that its siRNA drug Amvuttra® (vutrisiran) was approved by the FDA for the treatment of polyneuropathy with hereditary transthyretin-mediated amyloidosis (hATTR) in adults.

The report offers a comprehensive overview of the latest advancements in the pharmaceutical industry.

The report offers a comprehensive overview of the latest advancements in the pharmaceutical industry.

The report offers a comprehensive overview of the latest advancements in the pharmaceutical industry.